Prevalence of migraine in Saudi Arabia and the efficacy of Eptinezumab: A pooled analysis and Meta-analysis from clinical trials

Abstract

Eptinezumab 100 mg and 300 mg treated with intravenous over a 30-minute period on day 0 and week 12 showed prolonged migraine prevention effects. Eptinezumab has a high safety profile, despite expressing some minor side effects. Eptinezumab would be a promising treatment if it was approved in Saudi Arabia.